These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22066163)

  • 41. Testing for genetic predisposition to venous thrombosis.
    Marques MB
    MLO Med Lab Obs; 2002 Jan; 34(1):8-13; quiz 20-1. PubMed ID: 11828956
    [No Abstract]   [Full Text] [Related]  

  • 42. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quality assurance issues and interpretation of assays.
    Mackie I; Cooper P; Kitchen S
    Semin Hematol; 2007 Apr; 44(2):114-25. PubMed ID: 17433904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The molecular basis of inherited thrombophilia.
    Manucci PM
    Vox Sang; 2000; 78 Suppl 2():39-45. PubMed ID: 10938925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Appropriateness of choice and interpretation of tests for thrombophilic defects: a practical experience.
    Carraro P; Simioni P
    Clin Chim Acta; 2003 Jul; 333(2):191-3. PubMed ID: 12849904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia.
    Sas G; Blaskó G; Bánhegyi D; Jákó J; Pálos LA
    Thromb Diath Haemorrh; 1974 Sep; 32(1):105-15. PubMed ID: 4454033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Laboratory tests for protein C deficiency.
    Khor B; Van Cott EM
    Am J Hematol; 2010 Jun; 85(6):440-2. PubMed ID: 20309856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hematologic effects of thrombophilia.
    Fritsma GA; Southern DK
    Clin Lab Sci; 1998; 11(4):233-8. PubMed ID: 10182112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coexistence of three genetic risk factors in a Spanish thrombophilic family: Factor V Leiden, prothrombin 20210 and a new type I antithrombin deficiency.
    Ordóñez A; de Cos C; Miñano A; Rodríguez J; Hernández-Espinosa D; Muñoz JA; González-Conejero R; Vicente V; Corral J
    Thromb Haemost; 2007 Jan; 97(1):153-5. PubMed ID: 17200784
    [No Abstract]   [Full Text] [Related]  

  • 51. [Molecular methods in thrombophilic states diagnostics].
    Slavík L; Krcová V; Hlusí A; Procházková J; Ulehlová J
    Vnitr Lek; 2009 Mar; 55(3):302-9. PubMed ID: 19378863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.
    Villa P; Aznar J; Vaya A; España F; Ferrando F; Mira Y; Estellés A
    Thromb Haemost; 1999 Sep; 82(3):1011-4. PubMed ID: 10494755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
    Bombeli T; Raddatz-Mueller P; Fehr J
    Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
    Gheorghiade M; Thyssen A; Zolynas R; Nadar VK; Greenberg BH; Mehra M; Sun X; Tian H; Plotnikov AN; Burton P
    J Heart Lung Transplant; 2011 Feb; 30(2):218-26. PubMed ID: 20947383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental and clinical pharmacology of pentosan polysulfate.
    Maffrand JP; Herbert JM; Bernat A; Defreyn G; Delebassee D; Savi P; Pinot JJ; Sampol J
    Semin Thromb Hemost; 1991; 17 Suppl 2():186-98. PubMed ID: 1719639
    [No Abstract]   [Full Text] [Related]  

  • 56. Laboratory evaluation of hypercoagulability.
    Khor B; Van Cott EM
    Clin Lab Med; 2009 Jun; 29(2):339-66. PubMed ID: 19665682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct oral anticoagulant neutralization by activated charcoal DOAC-Remove for thrombophilia screening.
    Favre R; Zia-Chahabi S; Talb Y; de Gunzburg N; Flaujac C
    Blood Coagul Fibrinolysis; 2021 Jul; 32(5):356-358. PubMed ID: 34231503
    [No Abstract]   [Full Text] [Related]  

  • 58. [EQUALIS expert group for coagulation. Functional method for the first choice diagnostics of hereditary antithrombin deficiency].
    Strandberg K
    Lakartidningen; 2011 Aug 24-30; 108(34):1552. PubMed ID: 22066163
    [No Abstract]   [Full Text] [Related]  

  • 59. Antithrombin.
    Hepner M; Karlaftis V
    Methods Mol Biol; 2013; 992():355-64. PubMed ID: 23546728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.